COSCIENS Biopharma Inc
CSCI3.990USD
+0.170+4.45%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
12.55MValor de mercado
PerdaP/L TTM
Mais detalhes de COSCIENS Biopharma Inc Empresa
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Informações da empresa
Código da empresaCSCI
Nome da EmpresaCOSCIENS Biopharma Inc
Data de listagemDec 19, 1995
CEOMs. Anna Biehn
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 19
EndereçoC/O Norton Rose Fulbright Canada Llp
CidadeTORONTO
Bolsa de valoresThe Toronto Stock Exchange
PaísCanada
Código postalM5K 1E7
Telefone18439003201
Sitehttps://www.cosciensbio.com/
Código da empresaCSCI
Data de listagemDec 19, 1995
CEOMs. Anna Biehn
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Ms. Genevieve Foster
Ms. Genevieve Foster
Director
Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Director
Director
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Chairman of the Board
Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 1 de ago
Atualizado em: sex, 1 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
Investidores
Investidores
Proporção
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
8.19%
Individual Investor
1.49%
Investment Advisor
0.70%
Research Firm
0.11%
Bank and Trust
0.04%
Other
89.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
2023Q2
52
14.44K
1.19%
-13.85K
2023Q1
54
14.56K
1.20%
-15.46K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Goodwood Inc.
257.26K
8.18%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.33%
--
--
Mar 26, 2025
Susquehanna International Group, LLP
11.91K
0.38%
+11.91K
--
Mar 31, 2025
RBC Dominion Securities, Inc.
3.87K
0.12%
-69.00
-1.75%
Mar 31, 2025
TD Waterhouse Canada, Inc.
3.72K
0.12%
--
--
Mar 31, 2025
Desjardins Securities Inc.
2.81K
0.09%
-1.06K
-27.39%
Mar 31, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
UBS Financial Services, Inc.
2.34K
0.07%
+1.65K
+240.67%
Mar 31, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
National Bank of Canada
1.12K
0.04%
-4.80K
-81.05%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Data
Tipo
Proporção
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
